Fabrication of a Dual-Targeted Liposome-Coated Mesoporous Silica Core-Shell Nanoassembly for Targeted Cancer Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Nanoparticles offer controlled drug release and targeted delivery for chemotherapy.
• Reactive oxygen species (ROS) generation is a promising cancer treatment strategy.
• Combining chemotherapy and ROS generation could synergistically enhance cancer therapy.

Purpose of the Study:

• To develop a dual-targeted drug-delivery nanoassembly for synergistic cancer treatment.
• To load paclitaxel (Px), a ROS-generating chemotherapeutic, into mesoporous silica nanoparticles (MSN).
• To enhance targeting and controlled release using a liposome coating and lung cancer-specific ligands.

Main Methods:

• Fabrication of a dual-targeted nanoassembly (MSN@Px) L-GF using mesoporous silica core, paclitaxel, liposome coating, folic acid, and GE11 peptide.
• In vitro drug release studies to assess release kinetics.
• In vitro efficacy studies comparing the nanoassembly with free paclitaxel in cancer cells.

Main Results:

• The nanoassembly demonstrated controlled release of paclitaxel, with 65% released within 20 hours.
• Dual targeting ligands (folic acid and GE11) were successfully incorporated for specific lung cancer cell targeting.
• In vitro studies showed the nanoassembly was 8-fold more effective than free paclitaxel in cancer therapy.

Conclusions:

• The developed dual-targeted nanoassembly effectively delivers chemotherapy and generates ROS, leading to mitochondrial damage and cell death.
• This synergistic approach shows significant therapeutic potential for improving lung cancer treatment outcomes.
• The nanoassembly represents a promising platform for advanced cancer therapy by combining targeted drug delivery and ROS-mediated cell death.